CureVac has entered into a collaboration and pharma licensing agreement with Janssen Pharmaceuticals.
Under the pharma licensing agreement CureVac will collaborate with Crucell Holland on the development of an influenza vaccine based on CureVac's RNActive technology.
RNActive vaccines, based on CureVac's technology platform, have already demonstrated effectiveness and safety in several clinical trials.
Under the terms of the collaboration, CureVac will develop optimized RNActive vaccines based on Crucell's proprietary antigen sequences which will be tested in various models.
Additional details of the collaboration were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on Janssen company profile, recent partnering, M&A and financing news and articles
Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen
Report: Influenza Partnering 2007-2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity